Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Avidity Biosciences Stock News

RNANASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$30.93

At close: Apr 25 EDT

$30.71

-0.22-0.71%

Pre-Market: 4:58 AM EDT

Avidity Biosciences (RNA) Forecast

News

Earnings Avidity Biosciences (RNA) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Avidity Biosciences Stock News | NASDAQ:RNA | Benzinga

Get the latest news on Avidity Biosciences stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Avidity Biosciences performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, April 09, 2025

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock
Benzinga Insights - Apr 9, 2025, 10:01AM
Needham Reiterates Buy on Avidity Biosciences...
Benzinga Newsdesk - Apr 9, 2025, 8:41AM

Tuesday, April 08, 2025

Avidity Biosciences Receives Orphan Drug Desi...
Benzinga Newsdesk - Apr 8, 2025, 9:03AM

Monday, March 31, 2025

Avidity Biosciences Finalizes Enrollment In B...
Benzinga Newsdesk - Mar 31, 2025, 9:10AM

Tuesday, March 18, 2025

Forecasting The Future: 13 Analyst Projections For Avidity Biosciences
Benzinga Insights - Mar 18, 2025, 6:00PM
HC Wainwright & Co. Reiterates Buy on Avidity...
Benzinga Newsdesk - Mar 18, 2025, 1:00PM

Monday, March 17, 2025

Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025
Vandana Singh - Mar 17, 2025, 1:48PM
Needham Reiterates Buy on Avidity Biosciences...
Benzinga Newsdesk - Mar 17, 2025, 12:58PM
HC Wainwright & Co. Reiterates Buy on Avidity...
Benzinga Newsdesk - Mar 17, 2025, 11:14AM
Chardan Capital Maintains Buy on Avidity Bios...
Benzinga Newsdesk - Mar 17, 2025, 10:07AM
Avidity Biosciences Announced Del-Zota Toplin...
Benzinga Newsdesk - Mar 17, 2025, 7:05AM

Thursday, March 13, 2025

Citigroup Initiates Coverage On Avidity Biosc...
Benzinga Newsdesk - Mar 13, 2025, 9:36AM

Wednesday, March 12, 2025

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
Vandana Singh - Mar 12, 2025, 3:05PM
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Avi Kapoor - Mar 12, 2025, 12:57PM
Avidity Biosciences shares are trading higher...
Benzinga Newsdesk - Mar 12, 2025, 10:27AM
BMO Capital Initiates Coverage On Avidity Bio...
Benzinga Newsdesk - Mar 12, 2025, 5:25AM

Monday, March 10, 2025

B of A Securities Maintains Buy on Avidity Bi...
Benzinga Newsdesk - Mar 10, 2025, 12:56PM

Friday, March 07, 2025

Scotiabank Initiates Coverage On Avidity Bios...
Benzinga Newsdesk - Mar 7, 2025, 5:22PM

Friday, February 28, 2025

Barclays Maintains Overweight on Avidity Bios...
Benzinga Newsdesk - Feb 28, 2025, 5:05PM
Avidity Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Benzinga Insights - Feb 28, 2025, 8:00AM
Chardan Capital Maintains Buy on Avidity Bios...
Benzinga Newsdesk - Feb 28, 2025, 7:32AM

Tuesday, January 21, 2025

RBC Capital Reiterates Outperform on Avidity ...
Benzinga Newsdesk - Jan 21, 2025, 12:08PM

Friday, January 10, 2025

Analyst Expectations For Avidity Biosciences's Future
Benzinga Insights - Jan 10, 2025, 8:00AM
HC Wainwright & Co. Reiterates Buy on Avidity...
Benzinga Newsdesk - Jan 10, 2025, 7:38AM

Wednesday, January 08, 2025

Avidity Biosciences To File First BLA For Del...
Benzinga Newsdesk - Jan 8, 2025, 9:06AM

Friday, January 03, 2025

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Vandana Singh - Jan 3, 2025, 1:08PM

Friday, December 20, 2024

This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Avi Kapoor - Dec 20, 2024, 9:52AM
What 8 Analyst Ratings Have To Say About Avidity Biosciences
Benzinga Insights - Dec 20, 2024, 7:00AM
HC Wainwright & Co. Initiates Coverage On Avi...
Benzinga Newsdesk - Dec 20, 2024, 6:43AM

Tuesday, November 26, 2024

RBC Capital Initiates Coverage On Avidity Bio...
Benzinga Newsdesk - Nov 26, 2024, 4:53AM

Wednesday, November 13, 2024

Chardan Capital Maintains Buy on Avidity Bios...
Benzinga Newsdesk - Nov 13, 2024, 6:30PM
Avidity Biosciences shares are trading higher...
Benzinga Newsdesk - Nov 13, 2024, 9:55AM
Assessing Avidity Biosciences: Insights From 10 Financial Analysts
Benzinga Insights - Nov 13, 2024, 8:01AM
Needham Reiterates Buy on Avidity Biosciences...
Benzinga Newsdesk - Nov 13, 2024, 4:57AM

Tuesday, November 12, 2024

Avidity Biosciences Says It Is Opening Up New...
Benzinga Newsdesk - Nov 12, 2024, 7:40AM

Thursday, November 07, 2024

Avidity Biosciences Q3 EPS $(0.65) Beats $(0....
Benzinga Newsdesk - Nov 7, 2024, 5:11PM

Thursday, October 31, 2024

Needham Reiterates Buy on Avidity Biosciences...
Benzinga Newsdesk - Oct 31, 2024, 5:32AM

Wednesday, October 30, 2024

Chardan Capital Maintains Buy on Avidity Bios...
Benzinga Newsdesk - Oct 30, 2024, 9:27AM
Avidity Biosciences Pursues Potential Acceler...
Benzinga Newsdesk - Oct 30, 2024, 8:11AM

Monday, October 21, 2024

In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences
Benzinga Insights - Oct 21, 2024, 5:01PM
Evaluating Avidity Biosciences: Insights From 10 Financial Analysts
Benzinga Insights - Oct 21, 2024, 3:00PM
TD Cowen Maintains Buy on Avidity Biosciences...
Benzinga Newsdesk - Oct 21, 2024, 1:19PM

Monday, October 07, 2024

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Oct 7, 2024, 4:31PM

Thursday, October 03, 2024

Avidity Biosciences FDA Removed Partial Clini...
Benzinga Newsdesk - Oct 3, 2024, 7:06AM

Tuesday, September 24, 2024

Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
Vandana Singh - Sep 24, 2024, 2:15PM
Goldman Sachs Initiates Coverage On Avidity B...
Benzinga Newsdesk - Sep 24, 2024, 6:45AM

Wednesday, September 18, 2024

Cantor Fitzgerald Reiterates Overweight on Av...
Benzinga Newsdesk - Sep 18, 2024, 9:20AM

Monday, September 16, 2024

Unveiling 7 Analyst Insights On Avidity Biosciences
Benzinga Insights - Sep 16, 2024, 3:00PM
Cantor Fitzgerald Reiterates Overweight on Av...
Benzinga Newsdesk - Sep 16, 2024, 1:01PM

Monday, September 09, 2024

Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Vandana Singh - Sep 9, 2024, 2:28PM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved